{"protocolSection":{"identificationModule":{"nctId":"NCT02089464","orgStudyIdInfo":{"id":"NX92325"},"organization":{"fullName":"Nexstim Ltd","class":"INDUSTRY"},"briefTitle":"Niche Trial: Navigated Inhibitory rTMS to Contralesional Hemisphere Trial","officialTitle":"Pivotal Phase III, Prospective, Multicenter, Double Blinded, Randomized, Sham Controlled Trial to Determine the Therapeutic Effects of Navigation Guided 1 Hz rTMS Administered to the Contralesional Hemisphere as Adjuvant to Task Oriented Rehabilitation in Patients With Ischemic or Hemorrhagic Stroke","acronym":"NICHE"},"statusModule":{"statusVerifiedDate":"2020-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-04"},"primaryCompletionDateStruct":{"date":"2016-05","type":"ACTUAL"},"completionDateStruct":{"date":"2016-05","type":"ACTUAL"},"studyFirstSubmitDate":"2014-03-14","studyFirstSubmitQcDate":"2014-03-14","studyFirstPostDateStruct":{"date":"2014-03-17","type":"ESTIMATED"},"resultsFirstSubmitDate":"2020-08-04","resultsFirstSubmitQcDate":"2020-08-19","resultsFirstPostDateStruct":{"date":"2020-09-01","type":"ACTUAL"},"dispFirstSubmitDate":"2017-09-13","dispFirstSubmitQcDate":"2017-09-19","dispFirstPostDateStruct":{"date":"2017-09-27","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-08-19","lastUpdatePostDateStruct":{"date":"2020-09-01","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Nexstim Ltd","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"A pivotal, prospective, multi-center, randomized, controlled, double-blinded study combining active Nexstim NBS-guided 1Hz rTMS or sham-rTMS targeting the healthy hemisphere with standardized task oriented rehabilitation will be conducted in patients with post-stroke motor impairment. The therapy will be provided for 6 weeks and primary outcome assessed 6 months later."},"conditionsModule":{"conditions":["Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":199,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"NBS-rTMS + task-oriented rehabilitation","type":"ACTIVE_COMPARATOR","description":"NBS-guided rTMS + task-oriented rehabilitation","interventionNames":["Device: NBS-guided rTMS","Procedure: Task oriented rehabilitation"]},{"label":"Sham rTMS + task-oriented rehabilitation","type":"SHAM_COMPARATOR","description":"Sham rTMS + task-oriented rehabilitation","interventionNames":["Device: Sham rTMS","Procedure: Task oriented rehabilitation"]}],"interventions":[{"type":"DEVICE","name":"NBS-guided rTMS","armGroupLabels":["NBS-rTMS + task-oriented rehabilitation"],"otherNames":["Nexstim"]},{"type":"DEVICE","name":"Sham rTMS","armGroupLabels":["Sham rTMS + task-oriented rehabilitation"]},{"type":"PROCEDURE","name":"Task oriented rehabilitation","armGroupLabels":["NBS-rTMS + task-oriented rehabilitation","Sham rTMS + task-oriented rehabilitation"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Upper Extremity Fugl-Meyer Score","description":"Number of Participants with Improvement in Upper Extremity Fugl-Meyer (UEFM) Score at 6 Months Post-treatment equal or exceeding the Minimal Clinically Important Difference (MCID) of 5 points (MCID).","timeFrame":"Baseline - 6 months post-treatment"}],"secondaryOutcomes":[{"measure":"Arm-Research Action Test (ARAT)","description":"Scale minimum 0, maximum 57. Greater values indicate better motor function.","timeFrame":"Baseline - 6 months post-treatment"},{"measure":"Wolf Motor Function Test","description":"Time in seconds to perform test tasks. Shorter time indicates better motor function.","timeFrame":"Baseline - 6 months post-treatment"},{"measure":"NIH Stroke Scale (NIHSS)","description":"Scale is a measure of neurological functioning, with higher scores reflecting greater deficit (minimum 0,maximum 42)","timeFrame":"Baseline - 6 months post-treatment"},{"measure":"Chedoke-McMaster Stroke Assessment (CMSA)","description":"Scale minimum 1, maximum 7. Higher values indicate better motor function of hand.","timeFrame":"Baseline - 6 months post-treatment"},{"measure":"Stroke Impact Scale (SIS)","description":"Score used to detect the consequences of stroke on physical functioning and activities of daily living. The SIS-16 is a 16 item survey that inquires about daily tasks performed over the previous 2 weeks. Scale minimum 16, maximum 80. Higher values indicate better function","timeFrame":"Baseline - 6 months post-treatment"},{"measure":"Patient Health Questionnaire (PHQ9)","description":"The possible presence and severity of depression will be assessed using the Patient Health Questionnaire (PHQ9). PHQ9 is a scale with a minimum value 0 and maximum of 27. Higher values indicate more depressed mood","timeFrame":"Baseline - 6 months post-treatment"},{"measure":"Quality of Life Assessment: EuroQol EQ-5D Scale","description":"The EuroQoL EQ-5D is a visual analog scale scale from 0 (minimum) to 100 (maximum) assessing quality of life. Higher values indicate better quality of life.","timeFrame":"Baseline - 6 months post-treatment"}],"otherOutcomes":[{"measure":"To Assess Safety of Study Device Use, All Serious Adverse Events Will be Recorded and Compared Between Groups","description":"Serious Adverse Events were recorded and their occurrence was compared between treatment arms","timeFrame":"Baseline - 6 months post-treatment"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria :\n\n* ≥ 18 years of age\n* An ischemic or hemorrhagic stroke suffered 3-12 months prior to the study;\n* no other known brain abnormalities by history;\n* A one-sided stroke resulting in upper extremity paresis\n* A Chedoke-McMaster Stroke Assessment arm stage and hand stage of 3-6 for the affected limb\n\nExclusion Criteria\n\n* Implanted metallic parts of implanted electronic devices, including pacemakers, defibrillators, or implant medication pump;\n* Pregnant or trying to become pregnant; Lack of pregnancy established in females of child-bearing potential by a negative urine pregnancy test at screening.\n* Active alcohol abuse, illicit drug use or drug abuse or significant mental illness\n* Patients suffering from depression as measured by a score of \\>10 on the Patient Health Questionnaire (PHQ9). For clarity, patients diagnosed with depression which is controlled with stable anti-depressive medication and in whom PHQ9 is \\<10 are eligible to participate in the trial.\n* History of epilepsy, defined as at least two unprovoked seizures occurring greater than 24 hours apart or diagnosis of an epilepsy syndrome, OR a seizure within the last 12 months.\n* Any condition that would prevent the subject from giving voluntary informed consent;\n* An implanted brain stimulator;\n* Any metal in head with the exception of dental work or any ferromagnetic metal elsewhere in the body;\n* Enrolled or plans to enroll in an interventional trial during this study;\n* Scalp wounds or infections;\n* Claustrophobia precluding MRI;\n* A fixed contraction deformity in the affected limb that would prevent normal dexterity if patient were neurologically intact;\n* Excessive spasticity as indicated by the Modified Ashworth Spasticity (MAS) Scale \\>2/4 in either elbow flexors, wrist flexors or finger flexors of the affected limb;i\n* previous stroke with residual deficits (TIAs not a reason for exclusion);\n* premorbid (retrospective) modified Rankin Scale (mRS) score ≥2 of any aetiology;\n* a concurrent progressive neurologic disorder, acute coronary syndrome, severe heart disease (NYHA Classification \\> 3), or other major medical condition,\n* confirmed or suspected lower-limb fracture preventing mobilization,\n* patients requiring palliative care\n* patients planning to undergo any other occupational therapy during the 6 week active treatment period of the trial (see section 5.2 for study schedule) than what is provided in the study\n* A recent injection of botulinium toxin to the affected upper limb in the last 3 months, or the need of an injection of botulinum toxin anytime during the study period and follow up.\n* A recent injection of phenol to the affected upper limb in the last 6 months, or the need of an injection of phenol anytime during the study period and follow up.\n* Ataxia as measured by a score \\> 1 on item 7 (limb ataxia) of the NIH stroke scale.\n* Severe sensory deficits as measured by a score of 2 on item 8 of the NIH stroke scale.\n* Severe aphasia as measured by a score of \\> 2 on item 9 (best language) of the NIH stroke scale.\n* Severe neglect as measured by a score of 2 on item 11 (extinction and inattention) of the NIH stroke scale.\n* Patients unable to comprehend or follow verbal commands\n* Based on PI's or local physician's assessment patient unable to tolerate the trial procedure due to medical condition\n* A Mini mental status exam (MMSE) \\<25.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Richard L Harvey, MD","affiliation":"Shirley Ryan AbilityLab","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Mayo Clinic","city":"Phoenix","state":"Arizona","zip":"85054","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"Rancho Los Amigos National Rehabilitation Center","city":"Downey","state":"California","zip":"90242","country":"United States","geoPoint":{"lat":33.94001,"lon":-118.13257}},{"facility":"Shepherd Rehabilitation Center","city":"Atlanta","state":"Georgia","zip":"30309","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Rehabilitation Institute of Chicago","city":"Chicago","state":"Illinois","zip":"60611","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Indiana University Indianapolis","city":"Indianapolis","state":"Indiana","zip":"46202","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}},{"facility":"Spaulding Rehabilitation Hospital","city":"Boston","state":"Massachusetts","zip":"02129","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Columbia Cornell New York Presbyterian Hospital","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Burke Medical Research Institute, Weill Cornell Neurology","city":"White Plains","state":"New York","zip":"10605","country":"United States","geoPoint":{"lat":41.03399,"lon":-73.76291}},{"facility":"Duke University Medical Center","city":"Durham","state":"North Carolina","zip":"27705","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"University of Cincinnati","city":"Cincinnati","state":"Ohio","zip":"45267","country":"United States","geoPoint":{"lat":39.12713,"lon":-84.51435}},{"facility":"Ohio State University","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"TIRR Memorial Hermann Hospital","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}}]},"referencesModule":{"references":[{"pmid":"30354990","type":"RESULT","citation":"Harvey RL, Edwards D, Dunning K, Fregni F, Stein J, Laine J, Rogers LM, Vox F, Durand-Sanchez A, Bockbrader M, Goldstein LB, Francisco GE, Kinney CL, Liu CY; NICHE Trial Investigators *. Randomized Sham-Controlled Trial of Navigated Repetitive Transcranial Magnetic Stimulation for Motor Recovery in Stroke. Stroke. 2018 Sep;49(9):2138-2146. doi: 10.1161/STROKEAHA.117.020607."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"NBS-rTMS + Task-oriented Rehabilitation","description":"NBS-guided rTMS + task-oriented rehabilitation\n\nNBS-guided rTMS\n\nTask oriented rehabilitation"},{"id":"FG001","title":"Sham rTMS + Task-oriented Rehabilitation","description":"Sham rTMS + task-oriented rehabilitation\n\nSham rTMS\n\nTask oriented rehabilitation"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"132"},{"groupId":"FG001","numSubjects":"67"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"104"},{"groupId":"FG001","numSubjects":"51"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"28"},{"groupId":"FG001","numSubjects":"16"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"NBS-rTMS + Task-oriented Rehabilitation","description":"NBS-guided rTMS + task-oriented rehabilitation\n\nNBS-guided rTMS\n\nTask oriented rehabilitation"},{"id":"BG001","title":"Sham rTMS + Task-oriented Rehabilitation","description":"Sham rTMS + task-oriented rehabilitation\n\nSham rTMS\n\nTask oriented rehabilitation"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"132"},{"groupId":"BG001","value":"67"},{"groupId":"BG002","value":"199"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59.2","spread":"13.3"},{"groupId":"BG001","value":"57.6","spread":"12.7"},{"groupId":"BG002","value":"58.7","spread":"13.1"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"69"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"88"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"130"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"45"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"105"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"154"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"12"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"47"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"83"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"130"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"8"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"132"},{"groupId":"BG001","value":"67"},{"groupId":"BG002","value":"199"}]}]}]},{"title":"Upper Extremity Fugl-Meyer","description":"Scale minimum 0, maximum 66. Higher values indicate better motor function.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"34.0","spread":"12.2"},{"groupId":"BG001","value":"35.0","spread":"12.5"},{"groupId":"BG002","value":"34.3","spread":"12.3"}]}]}]},{"title":"Arm Research Action Test","description":"Scale minimum 0, maximum 57. Greater values indicate better motor function","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27.3","spread":"16.3"},{"groupId":"BG001","value":"30.0","spread":"15.8"},{"groupId":"BG002","value":"28.2","spread":"16.1"}]}]}]},{"title":"Wolf Motor Function Test","description":"Time in seconds to perform test tasks. Shorter time indicates better motor function.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"seconds of time","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"32.1","spread":"48.4"},{"groupId":"BG001","value":"29.4","spread":"46.8"},{"groupId":"BG002","value":"31.2","spread":"48.1"}]}]}]},{"title":"Chedoke-McMaster Stroke Assessment Hand","description":"Scale minimum 1, maximum 7. HIgher score indicates better function.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4.0","spread":"0.9"},{"groupId":"BG001","value":"4.1","spread":"1.0"},{"groupId":"BG002","value":"4.0","spread":"0.9"}]}]}]},{"title":"Chedoke-McMaster Stroke Assessment Arn","description":"Scale minimum 1, maximum 7. Higher values indicate better motor function.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3.5","spread":"0.8"},{"groupId":"BG001","value":"3.6","spread":"0.9"},{"groupId":"BG002","value":"3.5","spread":"0.9"}]}]}]},{"title":"NIH Stroke Scale","description":"Scale is a measure of neurological functioning, with higher scores reflecting greater deficit (minimum 0,maximum 42)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2.7","spread":"1.6"},{"groupId":"BG001","value":"2.3","spread":"1.9"},{"groupId":"BG002","value":"2.6","spread":"1.8"}]}]}]},{"title":"Stroke Impact Scale","description":"Score used to detect the consequences of stroke on physical functioning and activities of daily living. The SIS-16 is a 16 item survey that inquires about daily tasks performed over the previous 2 weeks. Scale minimum 16, maximum 80. Higher values indicate better function.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63.3","spread":"16.9"},{"groupId":"BG001","value":"65.3","spread":"16.0"},{"groupId":"BG002","value":"64.7","spread":"16.8"}]}]}]},{"title":"Patient Health Questionnaire - 9 (PHQ9)","description":"The possible presence and severity of depression will be assessed using the Patient Health Questionnaire (PHQ9). PHQ9 is a scale with a minimum value 0 and maximum of 27. Higher values indicate more depressed mood.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3.5","spread":"2.9"},{"groupId":"BG001","value":"3.7","spread":"3.2"},{"groupId":"BG002","value":"3.6","spread":"3.0"}]}]}]},{"title":"EuroQol ED-5Q scale","description":"The EuroQoL EQ-5D is a visual analog scale scale from 0 (minimum) to 100 (maximum) assessing quality of life. Higher values indicate better quality of life.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"68.2","spread":"18.4"},{"groupId":"BG001","value":"70.4","spread":"17.9"},{"groupId":"BG002","value":"68.8","spread":"18.3"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Upper Extremity Fugl-Meyer Score","description":"Number of Participants with Improvement in Upper Extremity Fugl-Meyer (UEFM) Score at 6 Months Post-treatment equal or exceeding the Minimal Clinically Important Difference (MCID) of 5 points (MCID).","populationDescription":"Intent to treat","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Baseline - 6 months post-treatment","groups":[{"id":"OG000","title":"NBS-rTMS + Task-oriented Rehabilitation","description":"NBS-guided rTMS + task-oriented rehabilitation\n\nNBS-guided rTMS\n\nTask oriented rehabilitation"},{"id":"OG001","title":"Sham rTMS + Task-oriented Rehabilitation","description":"Sham rTMS + task-oriented rehabilitation\n\nSham rTMS\n\nTask oriented rehabilitation"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"43"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.76","statisticalMethod":"Chi-squared"}]},{"type":"SECONDARY","title":"Arm-Research Action Test (ARAT)","description":"Scale minimum 0, maximum 57. Greater values indicate better motor function.","populationDescription":"Intent to treat","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline - 6 months post-treatment","groups":[{"id":"OG000","title":"NBS-rTMS + Task-oriented Rehabilitation","description":"NBS-guided rTMS + task-oriented rehabilitation\n\nNBS-guided rTMS\n\nTask oriented rehabilitation"},{"id":"OG001","title":"Sham rTMS + Task-oriented Rehabilitation","description":"Sham rTMS + task-oriented rehabilitation\n\nSham rTMS\n\nTask oriented rehabilitation"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"7.7"},{"groupId":"OG001","value":"5.0","spread":"10.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.80","statisticalMethod":"t-test, 2 sided"}]},{"type":"SECONDARY","title":"Wolf Motor Function Test","description":"Time in seconds to perform test tasks. Shorter time indicates better motor function.","populationDescription":"Intent to treat","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"seconds of time","timeFrame":"Baseline - 6 months post-treatment","groups":[{"id":"OG000","title":"NBS-rTMS + Task-oriented Rehabilitation","description":"NBS-guided rTMS + task-oriented rehabilitation\n\nNBS-guided rTMS\n\nTask oriented rehabilitation"},{"id":"OG001","title":"Sham rTMS + Task-oriented Rehabilitation","description":"Sham rTMS + task-oriented rehabilitation\n\nSham rTMS\n\nTask oriented rehabilitation"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.0","spread":"29.5"},{"groupId":"OG001","value":"-10.6","spread":"36.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.55","statisticalMethod":"Wilcoxon (Mann-Whitney)"}]},{"type":"SECONDARY","title":"NIH Stroke Scale (NIHSS)","description":"Scale is a measure of neurological functioning, with higher scores reflecting greater deficit (minimum 0,maximum 42)","populationDescription":"Intent to treat","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline - 6 months post-treatment","groups":[{"id":"OG000","title":"NBS-rTMS + Task-oriented Rehabilitation","description":"NBS-guided rTMS + task-oriented rehabilitation\n\nNBS-guided rTMS\n\nTask oriented rehabilitation"},{"id":"OG001","title":"Sham rTMS + Task-oriented Rehabilitation","description":"Sham rTMS + task-oriented rehabilitation\n\nSham rTMS\n\nTask oriented rehabilitation"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.3"},{"groupId":"OG001","value":"-0.7","spread":"1.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.14","statisticalMethod":"t-test, 2 sided"}]},{"type":"SECONDARY","title":"Chedoke-McMaster Stroke Assessment (CMSA)","description":"Scale minimum 1, maximum 7. Higher values indicate better motor function of hand.","populationDescription":"Intent to treat","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline - 6 months post-treatment","groups":[{"id":"OG000","title":"NBS-rTMS + Task-oriented Rehabilitation","description":"NBS-guided rTMS + task-oriented rehabilitation\n\nNBS-guided rTMS\n\nTask oriented rehabilitation"},{"id":"OG001","title":"Sham rTMS + Task-oriented Rehabilitation","description":"Sham rTMS + task-oriented rehabilitation\n\nSham rTMS\n\nTask oriented rehabilitation"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"1.0"},{"groupId":"OG001","value":"0.5","spread":"1.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.14","statisticalMethod":"t-test, 2 sided"}]},{"type":"SECONDARY","title":"Stroke Impact Scale (SIS)","description":"Score used to detect the consequences of stroke on physical functioning and activities of daily living. The SIS-16 is a 16 item survey that inquires about daily tasks performed over the previous 2 weeks. Scale minimum 16, maximum 80. Higher values indicate better function","populationDescription":"Intent to treat","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline - 6 months post-treatment","groups":[{"id":"OG000","title":"NBS-rTMS + Task-oriented Rehabilitation","description":"NBS-guided rTMS + task-oriented rehabilitation\n\nNBS-guided rTMS\n\nTask oriented rehabilitation"},{"id":"OG001","title":"Sham rTMS + Task-oriented Rehabilitation","description":"Sham rTMS + task-oriented rehabilitation\n\nSham rTMS\n\nTask oriented rehabilitation"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"11.6"},{"groupId":"OG001","value":"8.7","spread":"14.5"}]}]}]},{"type":"SECONDARY","title":"Patient Health Questionnaire (PHQ9)","description":"The possible presence and severity of depression will be assessed using the Patient Health Questionnaire (PHQ9). PHQ9 is a scale with a minimum value 0 and maximum of 27. Higher values indicate more depressed mood","populationDescription":"Intent to treat","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline - 6 months post-treatment","groups":[{"id":"OG000","title":"NBS-rTMS + Task-oriented Rehabilitation","description":"NBS-guided rTMS + task-oriented rehabilitation\n\nNBS-guided rTMS\n\nTask oriented rehabilitation"},{"id":"OG001","title":"Sham rTMS + Task-oriented Rehabilitation","description":"Sham rTMS + task-oriented rehabilitation\n\nSham rTMS\n\nTask oriented rehabilitation"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"3.3"},{"groupId":"OG001","value":"0.0","spread":"4.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.95","statisticalMethod":"t-test, 2 sided"}]},{"type":"SECONDARY","title":"Quality of Life Assessment: EuroQol EQ-5D Scale","description":"The EuroQoL EQ-5D is a visual analog scale scale from 0 (minimum) to 100 (maximum) assessing quality of life. Higher values indicate better quality of life.","populationDescription":"Intent to treat","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline - 6 months post-treatment","groups":[{"id":"OG000","title":"NBS-rTMS + Task-oriented Rehabilitation","description":"NBS-guided rTMS + task-oriented rehabilitation\n\nNBS-guided rTMS\n\nTask oriented rehabilitation"},{"id":"OG001","title":"Sham rTMS + Task-oriented Rehabilitation","description":"Sham rTMS + task-oriented rehabilitation\n\nSham rTMS\n\nTask oriented rehabilitation"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":"15.7"},{"groupId":"OG001","value":"6.9","spread":"14.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.96","statisticalMethod":"t-test, 2 sided"}]},{"type":"OTHER_PRE_SPECIFIED","title":"To Assess Safety of Study Device Use, All Serious Adverse Events Will be Recorded and Compared Between Groups","description":"Serious Adverse Events were recorded and their occurrence was compared between treatment arms","populationDescription":"Intent to treat","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"number of events","timeFrame":"Baseline - 6 months post-treatment","groups":[{"id":"OG000","title":"NBS-rTMS + Task-oriented Rehabilitation","description":"NBS-guided rTMS + task-oriented rehabilitation\n\nNBS-guided rTMS\n\nTask oriented rehabilitation"},{"id":"OG001","title":"Sham rTMS + Task-oriented Rehabilitation","description":"Sham rTMS + task-oriented rehabilitation\n\nSham rTMS\n\nTask oriented rehabilitation"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.63","statisticalMethod":"Chi-squared"}]}]},"adverseEventsModule":{"frequencyThreshold":"0","eventGroups":[{"id":"EG000","title":"NBS-rTMS + Task-oriented Rehabilitation","description":"NBS-guided rTMS + task-oriented rehabilitation\n\nNBS-guided rTMS\n\nTask oriented rehabilitation","deathsNumAffected":1,"deathsNumAtRisk":132,"seriousNumAffected":11,"seriousNumAtRisk":132,"otherNumAffected":30,"otherNumAtRisk":132},{"id":"EG001","title":"Sham rTMS + Task-oriented Rehabilitation","description":"Sham rTMS + task-oriented rehabilitation\n\nSham rTMS\n\nTask oriented rehabilitation","deathsNumAffected":0,"deathsNumAtRisk":67,"seriousNumAffected":7,"seriousNumAtRisk":67,"otherNumAffected":15,"otherNumAtRisk":67}],"seriousEvents":[{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":67}]},{"term":"Carotid artery disease","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Convulsion","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"VIIth nerve paralysis","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Pneumonia","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Device related infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Not study device involvement","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Hydronephrosis","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Hypertensive crisis","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"cardiac failure congestive","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Depression","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Coronary artery bypass","organSystem":"Surgical and medical procedures","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Hip surgery","organSystem":"Surgical and medical procedures","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Haemorrhagic anaemia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Thrombosis in device","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Not study device","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Hyperglycemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Prostate cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]}],"otherEvents":[{"term":"Headache","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":132},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":67}]},{"term":"Paresthesia","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":67}]},{"term":"Fatigue","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":132},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":67}]},{"term":"Spasms in hand","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Muscle spasticity","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Increased lacrimation","organSystem":"Eye disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Blepharospasm","organSystem":"Eye disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Dizziness","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":67}]},{"term":"Depression","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":132},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":67}]},{"term":"Panic attack","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Hallucination olfactory","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Hallucination auditory","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Photosensitivity reaction","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":67}]},{"term":"Tremor","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":132},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":67}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Vice President, Medical Affairs","organization":"Nexstim Plc","email":"jarmo.laine@nexstim.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2405","name":"Hemorrhagic Stroke","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]}},"hasResults":true}